Evidence map›Paper›PMID 40642006›Full record

ArticleFrontiers in pharmacology2025

Validating the antiseizure effects of vitexin and related flavone glycosides in zebrafish.

Audrey Breckenridge, Sanskriti Basnyat, Eva Fitch, Colleen Carpenter-Swanson

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Audrey Breckenridge *Department of Biology, University of Richmond, Richmond, VA, United States.
Sanskriti Basnyat *Department of Biology, University of Richmond, Richmond, VA, United States.
Eva FitchDepartment of Biology, University of Richmond, Richmond, VA, United States.
Colleen Carpenter-SwansonDepartment of Biology, University of Richmond, Richmond, VA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current epilepsy treatments often fail to provide sufficient control over seizures, highlighting the need for new therapeutic agents. Vitexin, a flavone with antioxidant, anti-inflammatory, and neuroprotective properties, was previously shown to suppress seizure activity in rodent models. Utilizing zebrafish, this study further evaluates the antiseizure properties of vitexin and for the first time, examines the related flavone glycosides: isovitexin, vitexin 2-O-rhamnoside, vitexin-4-O-glucoside and saponarin. We initially tested the ability of the compounds to reduce behavioral seizures stimulated by the GABA

Indexed as

behaviorepilepsyflavonoidsmultielectrode arrayvitexinzebrafish

Identifiers

PMID40642006
PMCPMC12241147

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.